8-K: TenX Keane Acquisition Secures Further Extension for Business Combination with $66,667 Deposit

TenX Keane Acquisition extended its deadline to complete a business combination to June 18, 2024, by securing a $66,667 deposit from Citius Pharma.

Summary

• TenX Keane Acquisition has extended its deadline to complete a business combination by one month, from May 18, 2024, to June 18, 2024.
• This extension was secured through a $66,667 deposit made by Citius Pharmaceuticals into the company's trust account.
• The deposit is structured as an unsecured promissory note from TenX Keane Acquisition to Citius Pharma.
• The note bears no interest and is repayable upon the consummation of a business combination, provided the trust account balance is at least $2,000,000.
• This is the second of a possible seven one-month extensions, with the first extension occurring on April 26, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the extension is a positive sign of continued effort, the need for multiple extensions introduces some uncertainty. The funding mechanism is standard, but the contingent repayment adds a layer of risk.

Positives

• The company has successfully secured an additional month to finalize its business combination.
• The funding mechanism through a promissory note is straightforward and avoids immediate cash outflow for TenX Keane Acquisition.
• The extension demonstrates continued commitment from Citius Pharma to the merger.

Negatives

• The need for multiple extensions suggests potential challenges in finalizing the business combination.
• The promissory note adds a liability to TenX Keane Acquisition's balance sheet, although it is contingent on the merger's success.
• The requirement for a $2,000,000 trust account balance for repayment adds a condition to the note.

Risks

• The business combination may not be completed by the new deadline of June 18, 2024, requiring further extensions.
• If the business combination fails, the promissory note may not be repaid.
• The trust account balance may not reach the required $2,000,000 threshold for repayment of the note.

Future Outlook

TenX Keane Acquisition has until June 18, 2024, to complete its business combination, with the possibility of further extensions if needed. The repayment of the promissory note is contingent on the successful completion of the merger and the trust account balance reaching $2,000,000.

Management Comments

• Xiaofeng Yuan, Chief Executive Officer and Chairman, signed the report on behalf of TenX Keane Acquisition.

Industry Context

This announcement is typical for SPACs (Special Purpose Acquisition Companies) that are nearing their deadline to complete a business combination. The extension and funding mechanism are common practices in the SPAC market.

Comparison to Industry Standards

• The use of a promissory note for extension funding is a standard practice among SPACs facing deadlines.
• The one-month extension period is also typical, as SPACs often seek short-term extensions to finalize deals.
• The $66,667 deposit is consistent with the terms outlined in the company's charter, which is a common structure for SPAC extensions.
• Other SPACs such as Gores Metropoulos II, Inc. and Churchill Capital Corp IV have also used similar extension mechanisms.

Related Party Transactions

• The promissory note issued to Citius Pharma is a related party transaction, as Citius Pharma is the designee of the Sponsor and a party to the merger agreement.

Stakeholder Impact

• Shareholders may experience uncertainty due to the extension of the business combination deadline.
• The extension provides more time for the company to finalize the merger, which could be beneficial for all stakeholders if successful.
• Creditors are not directly impacted by this transaction.

Next Steps

• TenX Keane Acquisition will continue to work towards completing its business combination with Citius Oncology by June 18, 2024.
• The company may seek further extensions if the business combination is not finalized by the deadline.

Key Dates

Keywords

business combination, extension, promissory note, Citius Pharmaceuticals, TenX Keane Acquisition, merger, trust account, SPAC